- Home
- GIG vs AVIR Comparison
GIG vs AVIR Comparison
Compare GIG & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIG
- AVIR
- Stock Information
- Founded
- GIG 2024
- AVIR 2012
- Country
- GIG United States
- AVIR United States
- Employees
- GIG N/A
- AVIR N/A
- Industry
- GIG
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- GIG
- AVIR Health Care
- Exchange
- GIG NYSE
- AVIR Nasdaq
- Market Cap
- GIG 331.0M
- AVIR 290.4M
- IPO Year
- GIG 2024
- AVIR 2020
- Fundamental
- Price
- GIG $9.89
- AVIR $3.46
- Analyst Decision
- GIG
- AVIR Hold
- Analyst Count
- GIG 0
- AVIR 1
- Target Price
- GIG N/A
- AVIR $6.88
- AVG Volume (30 Days)
- GIG 29.0K
- AVIR 251.7K
- Earning Date
- GIG 01-01-0001
- AVIR 11-06-2024
- Dividend Yield
- GIG N/A
- AVIR N/A
- EPS Growth
- GIG N/A
- AVIR N/A
- EPS
- GIG N/A
- AVIR N/A
- Revenue
- GIG N/A
- AVIR N/A
- Revenue This Year
- GIG N/A
- AVIR N/A
- Revenue Next Year
- GIG N/A
- AVIR N/A
- P/E Ratio
- GIG N/A
- AVIR N/A
- Revenue Growth
- GIG N/A
- AVIR N/A
- 52 Week Low
- GIG $9.89
- AVIR $2.77
- 52 Week High
- GIG $9.94
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- GIG N/A
- AVIR 40.35
- Support Level
- GIG N/A
- AVIR $3.30
- Resistance Level
- GIG N/A
- AVIR $3.41
- Average True Range (ATR)
- GIG 0.00
- AVIR 0.15
- MACD
- GIG 0.00
- AVIR -0.03
- Stochastic Oscillator
- GIG 0.00
- AVIR 11.18
About GIG GIGCAPITAL7 CORP.
GigCapital7 Corp is a Private-to-Public Equity (PPE) company, also known as a blank check company or special purpose acquisition company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).